BRIEF—Asahi Kasei Pharma obtains rights to added indication of Doptelet

Japan’s Asahi Kasei Pharma has concluded an agreement with Swedish Orphan Biovitrum Japan Co regarding exclusive distribution rights in Japan for the additional indication of idiopathic thrombocytopenic purpura (immune thrombocytopenia) for Doptelet (avatrombopag maleate), a thrombopoietin receptor agonist.

Doptelet was approved in Japan in March 2023 as an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure, and Asahi Kasei Pharma began marketing it in June 2023 based on exclusive distribution rights from Sobi Japan.

For the treatment of idiopathic thrombocytopenic purpura (immune thrombocytopenia), Doptelet has been approved in the USA, Europe, and elsewhere, and is currently the subject of a Phase III clinical study in Japan by Sobi Inc.